Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies
Go back to Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies| Merck & Co. (NYSE: MRK) | Delayed: 113.87 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $113.87 | 52 Week High | $65.46 | |||
| Open | $113.87 | 52 Week Low | $47.97 | |||
| Day High | $113.87 | P/E | 77.46 | |||
| Day Low | $113.87 | EPS | $1.47 | |||
| Volume | 3,960 | |||||
